|
1
|
Yi X, Luk JM, Lee NP, Peng J, Leng X, Guan
XY, Lau GK, Beretta L and Fan ST: Association of mortalin (HSPA9)
with liver cancer metastasis and prediction for early tumor
recurrence. Mol Cell Proteomics. 7:315–325. 2008. View Article : Google Scholar
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Farazi PA and DePinho RA: Hepatocellular
carcinoma pathogenesis: From genes to environment. Nat Rev Cancer.
6:674–687. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Uchino K, Tateishi R, Shiina S, Kanda M,
Masuzaki R, Kondo Y, Goto T, Omata M, Yoshida H and Koike K:
Hepatocellular carcinoma with extrahepatic metastasis: Clinical
features and prognostic factors. Cancer. 117:4475–4483. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nagahara K, Arikawa T, Oomizu S, Kontani
K, Nobumoto A, Tateno H, Watanabe K, Niki T, Katoh S, Miyake M, et
al: Galectin-9 increases Tim-3+ dendritic cells and
CD8+ T cells and enhances antitumor immunity via
galectin-9-Tim-3 interactions. J Immunol. 181:7660–7669. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fujihara S, Mori H, Kobara H, Rafiq K,
Niki T, Hirashima M and Masaki T: Galectin-9 in cancer therapy.
Recent Pat Endocr Metab Immune Drug Discov. 7:130–137. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wiersma VR, de Bruyn M, Helfrich W and
Bremer E: Therapeutic potential of Galectin-9 in human disease. Med
Res Rev. 33(Suppl 1): E102–E126. 2013. View Article : Google Scholar
|
|
8
|
Hirashima M, Kashio Y, Nishi N, Yamauchi
A, Imaizumi TA, Kageshita T, Saita N and Nakamura T: Galectin-9 in
physiological and pathological conditions. Glycoconj J. 19:593–600.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang F, He W, Zhou H, Yuan J, Wu K, Xu L
and Chen ZK: The Tim-3 ligand galectin-9 negatively regulates
CD8+ alloreactive T cell and prolongs survival of skin
graft. Cell Immunol. 250:68–74. 2007. View Article : Google Scholar
|
|
10
|
Freeman GJ, Casasnovas JM, Umetsu DT and
DeKruyff RH: TIM genes: A family of cell surface phosphatidylserine
receptors that regulate innate and adaptive immunity. Immunol Rev.
235:172–189. 2010.PubMed/NCBI
|
|
11
|
Sharma S, Sundararajan A, Suryawanshi A,
Kumar N, Veiga-Parga T, Kuchroo VK, Thomas PG, Sangster MY and
Rouse BT: T cell immunoglobulin and mucin protein-3
(Tim-3)/Galectin-9 interaction regulates influenza A virus-specific
humoral and CD8 T-cell responses. Proc Natl Acad Sci USA.
108:19001–19006. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Heusschen R, Griffioen AW and Thijssen VL:
Galectin-9 in tumor biology: A jack of multiple trades. Biochim
Biophys Acta. 1836:177–185. 2013.PubMed/NCBI
|
|
13
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kloosterman WP and Plasterk RH: The
diverse functions of microRNAs in animal development and disease.
Dev Cell. 11:441–450. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Garzon R, Marcucci G and Croce CM:
Targeting microRNAs in cancer: Rationale, strategies and
challenges. Nat Rev Drug Discov. 9:775–789. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xiong Y, Fang JH, Yun JP, Yang J, Zhang Y,
Jia WH and Zhuang SM: Effects of microRNA-29 on apoptosis,
tumorige-nicity, and prognosis of hepatocellular carcinoma.
Hepatology. 51:836–845. 2010.
|
|
19
|
Cosse JP and Michiels C: Tumour hypoxia
affects the responsiveness of cancer cells to chemotherapy and
promotes cancer progression. Anticancer Agents Med Chem. 8:790–797.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fourcade J, Sun Z, Benallaoua M, Guillaume
P, Luescher IF, Sander C, Kirkwood JM, Kuchroo V and Zarour HM:
Upregulation of Tim-3 and PD-1 expression is associated with tumor
antigen-specific CD8+ T cell dysfunction in melanoma
patients. J Exp Med. 207:2175–2186. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fourcade J, Kudela P, Sun Z, Shen H, Land
SR, Lenzner D, Guillaume P, Luescher IF, Sander C, Ferrone S, et
al: PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell
expansion in melanoma patients. J Immunol. 182:5240–5249. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hastings WD, Anderson DE, Kassam N,
Koguchi K, Greenfield EA, Kent SC, Zheng XX, Strom TB, Hafler DA
and Kuchroo VK: TIM-3 is expressed on activated human
CD4+ T cells and regulates Th1 and Th17 cytokines. Eur J
Immunol. 39:2492–2501. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kikushige Y, Shima T, Takayanagi S, Urata
S, Miyamoto T, Iwasaki H, Takenaka K, Teshima T, Tanaka T, Inagaki
Y, et al: TIM-3 is a promising target to selectively kill acute
myeloid leukemia stem cells. Cell Stem Cell. 7:708–717. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Thijssen VL, Hulsmans S and Griffioen AW:
The galectin profile of the endothelium: Altered expression and
localization in activated and tumor endothelial cells. Am J Pathol.
172:545–553. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Türeci O, Schmitt H, Fadle N, Pfreundschuh
M and Sahin U: Molecular definition of a novel human galectin which
is immu-nogenic in patients with Hodgkin's disease. J Biol Chem.
272:6416–6422. 1997. View Article : Google Scholar
|
|
26
|
Wada J, Ota K, Kumar A, Wallner EI and
Kanwar YS: Developmental regulation, expression, and apoptotic
potential of galectin-9, a beta-galactoside binding lectin. J Clin
Invest. 99:2452–2461. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Irie A, Yamauchi A, Kontani K, Kihara M,
Liu D, Shirato Y, Seki M, Nishi N, Nakamura T, Yokomise H, et al:
Galectin-9 as a prognostic factor with antimetastatic potential in
breast cancer. Clin Cancer Res. 11:2962–2968. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kageshita T, Kashio Y, Yamauchi A, Seki M,
Abedin MJ, Nishi N, Shoji H, Nakamura T, Ono T and Hirashima M:
Possible role of galectin-9 in cell aggregation and apoptosis of
human melanoma cell lines and its clinical significance. Int J
Cancer. 99:809–816. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lahm H, André S, Hoeflich A, Fischer JR,
Sordat B, Kaltner H, Wolf E and Gabius HJ: Comprehensive galectin
fingerprinting in a panel of 61 human tumor cell lines by RT-PCR
and its implications for diagnostic and therapeutic procedures. J
Cancer Res Clin Oncol. 127:375–386. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Asakura H, Kashio Y, Nakamura K, Seki M,
Dai S, Shirato Y, Abedin MJ, Yoshida N, Nishi N, Imaizumi T, et al:
Selective eosinophil adhesion to fibroblast via IFN-gamma-induced
galectin-9. J Immunol. 169:5912–5918. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhu C, Anderson AC, Schubart A, Xiong H,
Imitola J, Khoury SJ, Zheng XX, Strom TB and Kuchroo VK: The Tim-3
ligand galectin-9 negatively regulates T helper type 1 immunity.
Nat Immunol. 6:1245–1252. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sánchez-Fueyo A, Tian J, Picarella D,
Domenig C, Zheng XX, Sabatos CA, Manlongat N, Bender O, Kamradt T,
Kuchroo VK, et al: Tim-3 inhibits T helper type 1-mediated auto-
and allo-immune responses and promotes immunological tolerance. Nat
Immunol. 4:1093–1101. 2003. View
Article : Google Scholar
|
|
33
|
Li H, Wu K, Tao K, Chen L, Zheng Q, Lu X,
Liu J, Shi L, Liu C, Wang G, et al: Tim-3/galectin-9 signaling
pathway mediates T-cell dysfunction and predicts poor prognosis in
patients with hepatitis B virus-associated hepatocellular
carcinoma. Hepatology. 56:1342–1351. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang J, Yang Y, Yang T, Liu Y, Li A, Fu
S, Wu M, Pan Z and Zhou W: microRNA-22, downregulated in
hepatocellular carcinoma and correlated with prognosis, suppresses
cell proliferation and tumourigenicity. Br J Cancer. 103:1215–1220.
2010. View Article : Google Scholar : PubMed/NCBI
|
